Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023

January 26th 2024

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Role of Transplant in Myelofibrosis

January 26th 2024

Panel experts comment on the role of transplant in patients with myelofibrosis.

Corticosteroids and Clinical Trial Design in Chronic GVHD

January 25th 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the complexities of chronic GVHD management, highlighting recent developments and efforts to reduce reliance on steroids.

Targeted Treatments for GVHD

January 25th 2024

The GVHD experts discuss recent advancements in chronic GVHD treatment, focusing on agents ruxolitinib, ibrutinib, and belumosudil and their mechanisms of action. The panel emphasizes the need for ongoing research and clinical trials to refine treatment strategies.

Dr Davids on Treatment With Pirtobrutinib in CLL/SLL With/Without Prior BCL-2 Inhibitor Exposure

January 24th 2024

Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.

Vice President of ASH Will Focus on Gene Therapies, ASH’s Global Impact

January 24th 2024

The field of hematology is experiencing significant advancements as promising new therapies for malignancies and GVHD continue to emerge.

Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

January 23rd 2024

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Choosing CAR T-cells as Third-line and Beyond Therapy for FL

January 23rd 2024

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rituximab and Lenalidomide (R2) vs R2 Alone in Patients With Relapsed or Refractory Follicular Lymphoma

January 23rd 2024

Lorenzo Falchi, MD, discusses the ongoing EPCORE FL-1 phase 3 trial investigating epcoritamab-rituximab-lenalidomide vs rituximab-lenalidomide in patients with relapsed or refractory follicular lymphoma.

Obecabtagene Autoleucel BLA for Relapsed/Refractory B-ALL Under FDA Review

January 23rd 2024

The FDA has accepted for review the BLA for obecabtagene autoleucel's use in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Dr Patel-Donnelly on the Management of High-Risk Hematologic Malignancies in the Community

January 22nd 2024

Dipti Patel-Donnelly, MD, discusses the management of high-risk hematologic malignancies in community practice.

Patient Factors, Safety, and Long-Term Efficacy Best Inform Treatment Selection Across Hematologic Malignancies

January 22nd 2024

Michael Choi, MD, expands on significant advancements and treatment considerations in hematologic malignancies.

Olverembatinib Added to NCCN Guidelines for CML

January 22nd 2024

Olverembatinib has been added to the NCCN's latest 2024 guidelines for management of chronic myeloid leukemia.

Dr McCloskey on Flow Cytometry and Machine Learning in Hematologic Malignancy Diagnosis

January 20th 2024

James K. McCloskey, MD, discusses the potential for machine learning to replace flow cytometry analyses in patients with hematologic neoplasms.

Transplant Complications and Survival Outcomes

January 19th 2024

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

Supportive Care Measures for Patients Planning to Receive an Allogenic Transplant

January 19th 2024

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.

Hematologic Malignancies and Transplant Options and Conditioning Regimens Used in Allo-HSCT

January 19th 2024

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

FDA Grants Orphan Drug Designation to PTX-252 for AML

January 19th 2024

The FDA has granted an orphan drug designation to PTX-252 for the treatment of patients with acute myeloid leukemia.

MAJIC-PV: Clinical Implications in PV

January 19th 2024

Experts discuss the clinical implications of the MAJIC-PV trial.

Polycythemia Vera: Choosing the Right Treatment

January 19th 2024

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.